Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1984 May;25(5):630–632. doi: 10.1128/aac.25.5.630

Azlocillin pharmacokinetics in patients with cystic fibrosis.

J A Bosso, B A Saxon, J J Herbst, J M Matsen
PMCID: PMC185602  PMID: 6732230

Abstract

The pharmacokinetics of azlocillin were studied in 10 cystic fibrosis patients, ranging in age from 11 to 28 years. The patients received a 9- to 23-day course of 350 mg of azlocillin per kg in four or six divided daily doses in combination with am aminoglycoside. Blood and urine samples were collected at specified times after the last dose of the course of azlocillin therapy and then assayed for azlocillin content. Pharmacokinetic parameters were determined by noncompartmental analysis. Mean values for serum half-life (1.74 h), disposition constant (0.41 h-1), total body clearance (123 ml/kg per h), and renal clearance (58 ml/kg per h) were determined. All patients exhibited improvement with respect to clinical and laboratory parameters and displayed no adverse reactions. The pharmacokinetic analysis offers further evidence of the dose-dependent nature of azlocillin elimination, but elimination did not appear to be altered in cystic fibrosis patients.

Full text

PDF
630

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bennett J. V., Brodie J. L., Benner E. J., Kirby W. M. Simplified, accurate method for antibiotic assay of clinical specimens. Appl Microbiol. 1966 Mar;14(2):170–177. doi: 10.1128/am.14.2.170-177.1966. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bergan T. Overview of acylureidopenicillin pharmacokinetics. Scand J Infect Dis Suppl. 1981;29:33–48. [PubMed] [Google Scholar]
  3. Bergan T., Thorsteinsson S. B., Steingrimsson O. Dose-dependent pharmacokinetics of azlocillin compared to mezlocillin. Chemotherapy. 1982;28(3):160–170. doi: 10.1159/000238071. [DOI] [PubMed] [Google Scholar]
  4. Jusko W. J., Mosovich L. L., Gerbracht L. M., Mattar M. E., Yaffe S. J. Enhanced renal excretion of dicloxacillin in patients with cystic fibrosis. Pediatrics. 1975 Dec;56(6):1038–1044. [PubMed] [Google Scholar]
  5. Kearns G. L., Hilman B. C., Wilson J. T. Dosing implications of altered gentamicin disposition in patients with cystic fibrosis. J Pediatr. 1982 Feb;100(2):312–318. doi: 10.1016/s0022-3476(82)80663-x. [DOI] [PubMed] [Google Scholar]
  6. Kelly H. B., Menendez R., Fan L., Murphy S. Pharmacokinetics of tobramycin in cystic fibrosis. J Pediatr. 1982 Feb;100(2):318–321. doi: 10.1016/s0022-3476(82)80664-1. [DOI] [PubMed] [Google Scholar]
  7. Marks M. I. The pathogenesis and treatment of pulmonary infections in patients with cystic fibrosis. J Pediatr. 1981 Feb;98(2):173–179. doi: 10.1016/s0022-3476(81)80631-2. [DOI] [PubMed] [Google Scholar]
  8. Michalsen H., Bergan T. Pharmacokinetics of netilmicin in children with and without cystic fibrosis. Antimicrob Agents Chemother. 1981 Jun;19(6):1029–1031. doi: 10.1128/aac.19.6.1029. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Møller N. E., Eriksen K. R., Feddersen C., Flensborg E. W., Høiby N., Norn S., Rosendal K., Schiøtz P. O., Skov P. S. Chemotherapy against Pseudomonas aeruginosa in cystic fibrosis. A study of carbenicillin, azlocillin or piperacillin in combination with tobramycin. Eur J Respir Dis. 1982 Mar;63(2):130–139. [PubMed] [Google Scholar]
  10. Stevens P., Young L. S. Simple method for elimination of aminoglycosides from serum to permit bioassay of other antimicrobial agents. Antimicrob Agents Chemother. 1977 Aug;12(2):286–287. doi: 10.1128/aac.12.2.286. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES